Madison Area Lyme Support Group

The Ins and Outs of Methylene Blue

Methylene blue is a repurposed drug used to treat persister Lyme (Borrelia) and Bartonella. There is also lab evidence showing it treats growing Bartonella. It likely kills growing Lyme too. While methylene blue may treat growing germs, the main reason to use it in Lyme or Bartonella infectious is to treat persisters.

In this video article, Marty Ross, MD discusses the ins and outs, including risks factors, of using methylene blue. Below the video, you can find sample antibiotic protocols for Lyme and Bartonella that include methylene blue.

Notice-How to Use This Article

Be aware, most of the important information in this article is in the video in the top link

(See link for article and video)

______________

**Comment**

Methylene blue, like DMSO and ozone are more like therapeutic principles than drugs and work for many disease processes including COVID, yet mainstream medicine & media is remarkably silent because these safe, cheap, effective alternatives interfere with their conflicts of interest.  The same can be said for ivermectin and HCQ/zinc, as well as long-term antibiotics for Lyme/MSIDS sufferers who continue to have symptoms.

• https://madisonarealymesupportgroup.com/2022/07/11/methylene-blue-magic-bullet 

For more on Bartonella treatment:

• https://madisonarealymesupportgroup.com/2016/01/03/bartonella-treatment/
• https://madisonarealymesupportgroup.com/2022/01/18/clinical-spectrum-of-persistent-bartonella-infection-and-considerations-in-diagnosis-treatment/
• https://madisonarealymesupportgroup.com/2019/05/05/good-news-for-bartonella-patients-identification-of-fda-approved-drugs-with-higher-activity-than-current-front-line-drugs/  Please note that MB is listed.

For more on MB for COVID:

• https://www.nature.com/articles/s41598-021-92481-9  MB displays broad-spectrum virucidal activity in the presence of UV light and inactivates various viruses in blood products prior to transfusions.  It’s validated for treating methemoglobinemia and malaria.  Our findings reveal that methylene blue displays virucidal preventive or therapeutic activity against influenza virus H1N1 and SARS-CoV-2 at low micromolar concentrations and in the absence of UV-activation. We also confirm that MB antiviral activity is based on several mechanisms of action as the extent of genomic RNA degradation is higher in presence of light and after long exposure. Our work supports the interest of testing methylene blue in clinical studies to confirm a preventive and/or therapeutic efficacy against both influenza virus H1N1 and SARS-CoV-2 infections.
• https://biomedres.us/pdfs/BJSTR.MS.ID.006723.pdfSeven outpatients with confirmed cases of severe COVID-19 received oral MB (the reduced form: 1mg/kg T.I.D. for 2-days, followed by 1mg/kg B.I.D. for the next 12 days) along with standard care. Outpatients recovered completely.  Considering all properties of MB such as anti-viral, antibiotic, anticoagulant, immunomodulatory, antioxidants, anti-hypoxemia, and anti-respiratory; it could be applied as an adjunct therapy along with standard care protocols in the clinical management of COVID-19 outpatients. MB is a cheap and FDA-approved drug for methemoglobinemia.
• https://www.news-medical.net/news/20220325/Study-finds-methylene-blue-is-a-low-micromolar-inhibitor-of-the-the-SARS-CoV-2-spike-protein-and-ACE2-interaction.aspx  Authors of this study revealed that MeBlu is a low‐micromolar inhibitor of the PPI that suppresses interaction between the S protein of SARS-CoV-2 and its cognate receptor ACE2. The dye was also found to be effective against the Delta variant and to suppress virus replication in Vero E6 cells. Scientists believe that MeBlu could be used as an inexpensive drug for the treatment of SARS-CoV-2 infection.
• https://clinicaltrials.gov/ct2/show/NCT04933864  Since methylene blue can work as a photosensitizer, photodynamic therapy as an antiviral treatment has great potential in the treatment of COVID-19. (The study is ongoing so results are yet to be known)
• https://pubmed.ncbi.nlm.nih.gov/34019535/  The addition of MB to the treatment protocols significantly improved SpO₂ and respiratory distress in COVID-19 patients, which resulted in decreased hospital stay and mortality.
• https://www.frontiersin.org/articles/10.3389/fphar.2020.600372/full  Screening of our organic dye-based library identified MeBlu as a low-micromolar inhibitor of the interaction between SARS-CoV-2 spike protein and its cognate receptor ACE2, a PPI that is the first critical step initiating the viral entry of this coronavirus. While MeBlu shows strong polypharmacology and might be a somewhat promiscuous PPI inhibitor, its ability to inhibit this PPI could contribute to the antiviral activity of MeBlu against SARS-CoV-2 even in the absence of light making this inexpensive and widely available drug potentially useful in the prevention and treatment of COVID-19 as an oral or inhaled medication.
• https://www.sciencedirect.com/science/article/pii/S0753332221008064  Currently, the treatment of COVID-19 involves use of antiviral and anti-cytokine drugs. However, both the drugs have low efficacy because they cannot inhibit the production of free radicals and cytokines at the same time. Recently, some researchers have reported the use of methylene blue(MB) in COVID-19 management. MB has been used since a long time as a therapeutic agent, and has been approved by the US FDA for the treatment of other diseases. The additional advantage of MB is its low cost. MB is a safe drug when used in the dose of < 2 mg/kg. In this review, the applicability of MB in COVID-19 and its mechanistic aspects have been explored and compiled. The clinical studies have been explained in great detail. Thus, the potential of MB in the management of COVID-19 has been examined.  The results are satisfactory and provide a ray of hope in this direction. Thus, MB can be termed as a “rescue magic bullet” for COVID-19 treatment. However, for MB administration, meticulous consideration of the dosage is necessary to prevent any untoward effects. MB can be administered thrice orally at a dose of 2–3 mg/kg per day for 7–10 days in newly infected COVID-19 patients. However, this needs to be further studied, and finding the optimal dosage should be the objective of clinical study [43]. The use of MB in novel dosage forms like an anti-COVID mouthwash may also be beneficial [77].  **Warning** MB can interact with antidepressants (selective serotonin reuptake inhibitors and MAO inhibitors) to cause sever toxicity of serotonin.  It also has been found to interact with with dapsoneto form hydroxylamine, which oxidizes hemoglobin and may cause hemolysis [84]. Also, MB is contraindicated in patients with severe renal insufficiency. The use of MB in patients with G6PD deficiency can be detrimental, as it may cause severe hemolysis [53]. In such cases, the use of vitamin B12 and ascorbic acid has proven to be beneficial [85], [86], [87]. Additionally, concomitant use of NSAIDs may block the bradykinin activity pathways. Thus, NSAIDs may add benefit to MB therapy in COVID-19 [64], [88].